Conflicting results have been reported in previous retrospective analyses in EGFR+ NSCLC regarding the ability of LT to improve intracranial tumor control and OS,16, 17, 18, 19 while no similar study exists for ALK+ patients, and prospective data are lacking. This evidence concerns the gene ALK and non-small cell lung carcinoma.